Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Common-Size Balance Sheet: Assets

Paying user area

Try for free

AbbVie Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

AbbVie Inc., common-size consolidated balance sheet: assets

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and equivalents
Short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other
Current assets
Investments
Property and equipment, net
Intangible assets, net
Goodwill
Other assets
Long-term assets
Total assets

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. AbbVie Inc. current assets as a percentage of total assets increased from 2021 to 2022 and from 2022 to 2023.
Property and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. AbbVie Inc. property and equipment, net as a percentage of total assets increased from 2021 to 2022 and from 2022 to 2023.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. AbbVie Inc. long-term assets as a percentage of total assets decreased from 2021 to 2022 and from 2022 to 2023.